Frequent PD-L1 expression in testicular germ cell tumors

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Testicular germ cell cancers are often curable, but 10-15% resist first-line cisplatin treatment.
• Immunotherapy, specifically targeting Programmed Death Receptor 1 (PD-1) and Programmed Death Receptor Ligand 1 (PD-L1) interactions, is a potential treatment avenue.
• Understanding PD-L1 expression in these tumors is crucial for evaluating immunotherapy efficacy.

Purpose of the Study:

• To analyze the expression of PD-L1 in testicular germ cell tumors.
• To assess the potential of PD-L1 as a target for immunotherapy in testicular cancer.

Main Methods:

• Immunohistochemistry was performed on 479 formalin-fixed paraffin-embedded specimens.
• The study included seminomas, non-seminomas, intratubular germ cell neoplasia unclassified (IGCNU), and non-neoplastic testicular tissue.
• A rabbit monoclonal antibody (E1L3N) was used to detect PD-L1 expression.

Main Results:

• PD-L1 expression was observed in 73% of seminomas and 64% of non-seminomas.
• No PD-L1 expression was detected in IGCNU or normal testicular tissue.
• PD-L1 showed predominantly membranous staining in tumor cells and was also found in stromal cells of seminomas.

Conclusions:

• Frequent PD-L1 expression in testicular germ cell tumors suggests immunotherapy is a viable strategy.
• Patients with testicular germ cell tumors may benefit from immunotherapeutic approaches using anti-PD1 and anti-PDL1 antibodies.
• PD-L1 serves as a promising biomarker for guiding immunotherapy in testicular cancer.